Ampio Pharmaceuticals, Inc. focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States.Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial. AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation, AP-019, an Inhaled Ampion treatment.
